What is claimed is:

1. A method for inhibiting the proliferation, differentiation, or development of stem cells or cancer stem cells in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product.

2. The method of claim 1, wherein said antagonist is administered in combination with one or more additional anti-cancer therapies.

3. The method of claim 2 wherein the additional anti-cancer therapy is surgery, radiation therapy, or administration of a chemotherapeutic agent.

4. The method of claim 2, wherein the antagonist of an Hs.459642 Unigene Cluster product is administered prior to the additional anti-cancer therapy.

5. The method of claim 2, wherein the antagonist of an Hs.459642 Unigene Cluster product and the additional anti-cancer therapy are administered simultaneously.

6. The method of claim 2 wherein said Hs.459642 Unigene Cluster product antagonist is an Hs.459642 Unigene Cluster product-specific antibody.

7. The method of claim 6 wherein the Hs.459642 Unigene Cluster product-specific antibody is polyclonal or monoclonal.

8. The method of claim 7 wherein the Hs.459642 Unigene Cluster product-specific antibody is a fully or partially humanized monoclonal antibody.

9. The method of claim 1 wherein the antagonist is an antisense oligonucleotide antagonist.

10. The method of any of claims 1-9 wherein the Hs.459642 Unigene Cluster product is CACNA1H.

11. A pharmacologic composition that comprises an antagonist of the activity of an Hs.459642 Unigene Cluster product, wherein said composition inhibits proliferation, differentiation, or development of stem cells and cancer stem cells.

12. The composition of claim 11, wherein the antagonist is an antibody that antagonizes a Hs.459642 Unigene Cluster product.

13. The composition of claim 12, wherein the antibody is polyclonal or monoclonal.

14. The composition of claim 14, wherein the antibody is a fully or partially humanized monoclonal antibody.

15. The composition of claim 11, wherein the antagonist is an antisense oligonucleotide antagonist.

16. The composition of any of claims 11-15, wherein the Hs.459642 Unigene Cluster product is CACNA1H.

17. An antibody that antagonizes an Hs.459642 Unigene Cluster product.

18. The antibody of claim 17, wherein the antibody is polyclonal or monoclonal.

19. The antibody of claim 18, wherein the antibody is a fully or partially humanized monoclonal antibody.

20. The antibody of any of claims 17-19, wherein the Hs.459642 Unigene Cluster product is CACNA1H.

21. An antisense oligonucleotide that antagonizes an Hs.459642 Unigene Cluster product.

22. The antisense oligonucleotide of claim 21, wherein the Hs.459642 Unigene Cluster product is CACNA1H.

CLAIMS

1. An invention not claimed in any divisional application.